ODYSSEY Outcomes results build on FOURIER

ORLANDO – The ODYSSEY Outcomes trial proves the point that LDL-cholesterol reduction with PCSK9 inhibitors can reduce not only cardiovascular events, but all-cause mortality, Prakash Deedwania, MD, said in an interview at the annual meeting of the American College of Cardiology.

That mortality reduction builds on the FOURIER trial results, which showed last year that evolocumab significantly reduced cardiovascular events in patients with stable atherosclerotic cardiovascular disease who were still at residual risk based on elevated LDL cholesterol levels said Dr. Deedwania, professor of medicine at the University of California, San Francisco, in Fresno, who was not involved with ODYSSEY Outcomes.

However, one finding about mortality in ODYSSEY Outcomes was disappointing: LDL levels increase slightly over time in both the treatment and placebo groups.

Source: Deedwania P ACC 18.